Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

306.85
Delayed Data
As of 3:59pm ET
 -2.48 / -0.80%
Today’s Change
223.02
Today|||52-Week Range
333.65
+0.16%
Year-to-Date
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug 24 / Zacks.com - Paid Partner Content
Ionis Pharmaceuticals Inc Begins to Shift Focus
Aug 16 / MotleyFool.com - Paid Partner Content
Biotechs Rally on Pfizer/Medivation Deal
Aug 22 / TheStreet.com - Paid Partner Content
Top 3 Research Reports for August 15, 2016
Aug 15 / Zacks.com - Paid Partner Content
9 Stocks Smart Investors Put Their Money in Last Quarter
Aug 20 / TheStreet.com - Paid Partner Content
Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Aug 15 / Zacks.com - Paid Partner Content
Gilead May Be Better Off Splitting Itself in Two, Analysts Say
Aug 18 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Aug 12 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Aug 17 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Aug 11 / Zacks.com - Paid Partner Content
Better Buy: Amgen Inc. vs. Biogen
Aug 17 / MotleyFool.com - Paid Partner Content
Biogen and Ionis Pharmaceuticals climb on upbeat drug trials
Aug 01 / FT.com - Paid Partner Content